SUBSCRIBE
SUBSCRIBE
News   Drug Development

Analyst: Roche May Drop Taspoglutide Diabetes Drug

June 28, 2010 | 
1 min read
IndyStar -- Roche Holding AG may drop development of the taspoglutide diabetes drug and return the rights to developer Ipsen SA because the treatment has too many side effects, Morgan Stanley analysts said.
Clinical research Phase II
Roche
MORE ON THIS TOPIC
Creative collage image young man builder architect engineer occupation lungs healthcare illness disease drawing background.
Lung cancer
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
September 8, 2025
 · 
2 min read
 · 
Tristan Manalac
graphic pattern with the tablet. topic of drugs. pill with girl and space inside. relax
Psychedelics
With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’
September 5, 2025
 · 
3 min read
 · 
Dan Samorodnitsky
Sanofi's Distribution Center in Quebec, Canada
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
September 5, 2025
 · 
2 min read
 · 
Tristan Manalac
halftone magazine style banner, dislike, negative rating, hand thumbs down
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
 · 
4 min read
 · 
Annalee Armstrong